Intended use: Rejoyn is a digital therapeutic intended for the treatment of depressive
disorder episodes in adults. It is intended to be used alongside usual care provided by a Healthcare
Professional.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/
or search for MHRA
Yellow Card in the Google Play or Apple App Store.
To report Rejoyn side effects or quality complaints,
contact +44 (0) 808 168 6726 or OPUKSafety@otsuka.co.uk
This portal has been developed and funded by Otsuka Pharmaceutical Europe Ltd. and
is for healthcare professionals only. All patient details will be kept based on our privacy notice.
If you are a patient or member of the public and you would like to learn more about Rejoyn, click here.
